Pleco, established in 2018, develops fixed-dose combinations (FDCs) for the treatment of cancer. These FDCs modify the cancer-generating environment by reducing the high load of known carcinogenic compounds that have accumulated in the body over many years. At MD Anderson Cancer Center in Houston, Texas, investigators have established that these carcinogenic compounds contribute to relapses in leukaemia patients.
All components in our FDCs are known active pharmaceutical ingredients (APIs) with established safety and efficacy profiles. Repurposing of existing therapies for alternative diseases is an attractive approach that saves significant investments of time and money during development.
Area of work
Developing new products in the field of cancer medicine